编前语：在医药创新的浪潮中，中国药企正从“跟跑者”向“领航者”转变。从PD-1单抗的出海突围，到东南亚市场的本土化深耕，从License-out（对外授权）到合资建厂，中国创新药企的国际化步伐不断加速。然而，这条路上既有星辰大海，也有暗礁险滩。南都健闻就此推出《破冰与暗礁：中国药企全球化深水区突围》系列报道的第二期。解码头部企业如何在迷雾重重的国际市场中点亮“灯塔”，探索差异化的出海战略。...
Source Link编前语：在医药创新的浪潮中，中国药企正从“跟跑者”向“领航者”转变。从PD-1单抗的出海突围，到东南亚市场的本土化深耕，从License-out（对外授权）到合资建厂，中国创新药企的国际化步伐不断加速。然而，这条路上既有星辰大海，也有暗礁险滩。南都健闻就此推出《破冰与暗礁：中国药企全球化深水区突围》系列报道的第二期。解码头部企业如何在迷雾重重的国际市场中点亮“灯塔”，探索差异化的出海战略。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.